Prospective Randomized Study on the Efficacy of Endoscopic Injection Therapy With Fibrin Sealant Versus Endoscopic Ligature for Acute Hemostasis and the Prophylaxis of Recurrent Bleeding From Esophageal Varices

Baxter Healthcare Corporation12 sites in 1 countryDecember 2000

ConditionsEsophageal and/or Gastric Varices

DrugsFibrin Sealant

Overview

Phase: Phase 3
Intervention: Not specified
Conditions: Esophageal and/or Gastric Varices
Sponsor: Baxter Healthcare Corporation
Locations: 12
Status: Completed
Last Updated: 19 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

The purpose of this study was to assess whether endoscopic sclerotherapy with Fibrin Sealant was superior to ligature, with or without Polidocanol, in achieving hemostasis in bleeding esophageal varices and preventing rebleeding. Therapeutic success was defined as survival of the first seven days without clinically significant bleeding.

Registry

clinicaltrials.gov

Start Date

December 2000

End Date

January 2004

Last Updated

19 years ago

Study Type

Interventional

Study Design

Parallel

Sex

All

Investigators

Sponsor

Baxter Healthcare Corporation

Eligibility Criteria

Inclusion Criteria

•Included in the study were patients with proven bleeding from esophageal varices due to liver cirrhosis:
•with a minimum age of 18 years,
•with bleeding symptoms (hematemesis, melena, hematochezia, hypotension, tachycardia) that had lasted not longer than 48 hours prior to hospital admission,
•who were expected to be hospitalized for at least seven days,
•who agreed to participate in the study.
•Randomization did not take place if another therapy was medically indicated for any reason.

Exclusion Criteria

•Patients were excluded from the study:
•in whom introduction of an endoscope was not possible for technical reasons,
•who had received an alternative endoscopic treatment to eradicate varices during the last three months (sclerotherapy, ligation),
•who had proven additional fundus bleeding from varices or bleeding from a hypertensive gastropathy,
•who had end stage tumor disease or end stage liver cirrhosis (Child Pugh class C with organ complications, such as hepatonephric syndrome, infected ascites etc.),
•who were pregnant or breast feeding,
•who had a known pulmonary disease combined with restricted lung function or right ventricular failure,
•who had congenital or acquired coagulopathies of non-hepatic origin,
•who were currently participating or had participated in another study during the past 30 days or had already been included in this study once,
•who were treated with drugs to decrease portal vein pressure (somatostatin, somatostatin analogs, terlipressin, glycylpressin, except β-blockers and nitrates),